Ramucirumab: all 119 studies that test it
Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaNot yet recruitingNCT07763171Phase 3
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingNCT07594548Phase 1
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
- Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesRecruitingNCT06675136Phase 1
- A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver MetastasisNot yet recruitingNCT06564298Phase 2
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingNCT06445972Phase 1/2
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06031688Phase 2
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
- Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .RecruitingNCT05927857Phase 1/2
- T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaRecruitingNCT05894824Phase 1/2
- Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Phase 1
- Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab MaintenanceRecruitingNCT04332367Phase 2
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingNCT04205968Phase 2
- Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)RecruitingNCT04040361Phase 2
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric CancerTerminatedNCT05071053Phase 2Results posted
- Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction CaCompletedNCT04921904Phase 1/2Results posted
- Pembrolizumab Plus Ramucirumab in Metastatic Gastric CancerCompletedNCT04632459Phase 2Results posted
- A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced CancerTerminatedNCT04557384Phase 1Results posted
- A Study of Ramucirumab (LY3009806) in Healthy ParticipantsCompletedNCT04495478Phase 1Results posted
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)TerminatedNCT04394624Phase 2Results posted
- CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial SarcomaTerminatedNCT04145700Phase 1/2Results posted
- CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell TumorCompletedNCT04145349Phase 1/2Results posted
- Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung CancerCompletedNCT04120454Phase 2Results posted
- Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 ImmunotherapyTerminatedNCT03904108Phase 2Results posted
- Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by SurgeryCompletedNCT03694002Phase 2Results posted
- Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLCCompletedNCT03689855Phase 2Results posted
- TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaCompletedNCT03686488Phase 2Results posted
- Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03650764Phase 1/2Results posted
- Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated MesotheliomaTerminatedNCT03502746Phase 2Results posted
- Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaCompletedNCT03141034Phase 2Results posted
- Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryCompletedNCT03008278Phase 1/2Results posted
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Phase 3Results posted
- A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsCompletedNCT02795858Phase 2Results posted
- A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung CancerCompletedNCT02789345Phase 1Results posted
- Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT02730247Phase 2Results posted
- Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric CancerTerminatedNCT02726399Phase 2Results posted
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerActive, not recruitingNCT02711553Phase 2Results posted
- A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid TumorsTerminatedNCT02597036Phase 1Results posted
- Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic CancerCompletedNCT02581215Phase 2Results posted
- A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsCompletedNCT02564198Phase 1Results posted
- A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT02539225Phase 2Results posted
- Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by SurgeryCompletedNCT02520141Phase 2Results posted
- A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric CancerCompletedNCT02514551Phase 2Results posted
- A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) CancerCompletedNCT02443883Phase 2Results posted
- A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-FetoproteinCompletedNCT02435433Phase 3Results posted
- A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial CancerCompletedNCT02426125Phase 3Results posted
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results posted
- Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal CancerCompletedNCT02317991Phase 2Results posted
- A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach CancerCompletedNCT02314117Phase 3Results posted
- PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond ProgressionCompletedNCT02213289Phase 2Results posted
- A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerCompletedNCT02082210Phase 1/2Results posted
- A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver CancerCompletedNCT02069041Phase 1Results posted
- A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction CancerCompletedNCT01983878Phase 2Results posted
- A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung CancerCompletedNCT01703091Phase 2Results posted
- A Study in Participants With Advanced Solid TumorsCompletedNCT01682135Phase 1Results posted
- A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRICompletedNCT01634555Phase 2Results posted
- A Study of Ramucirumab and Docetaxel in Participants With Solid TumorsCompletedNCT01567163Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid TumorsCompletedNCT01515306Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast CancerCompletedNCT01427933Phase 2Results posted
- A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)CompletedNCT01286818Phase 1Results posted
- Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis CarcinomaCompletedNCT01282463Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) in Participants With Breast CancerCompletedNCT01256567Phase 1Results posted
- Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric AdenocarcinomasCompletedNCT01253525Phase 1Results posted
- A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal CancerCompletedNCT01246960Phase 2Results posted
- Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer PatientsCompletedNCT01234402Phase 2Results posted
- A Study in Second Line Metastatic Colorectal CancerCompletedNCT01183780Phase 3Results posted
- A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric AdenocarcinomaCompletedNCT01170663Phase 3Results posted
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based ChemotherapyCompletedNCT01168973Phase 3Results posted
- A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01160744Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With SorafenibCompletedNCT01140347Phase 3Results posted
- A Study of Ramucirumab or Icrucumab in Colorectal CancerCompletedNCT01111604Phase 2Results posted
- Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing ChemotherapyCompletedNCT01079780Phase 2Results posted
- Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval ChangesCompletedNCT01017731Phase 2Results posted
- Study of IMC-1121B in Patients With Advanced Solid TumorsCompletedNCT01005355Phase 1Results posted
- Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and AdenocarcinomaCompletedNCT00917384Phase 3Results posted
- Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00895180Phase 2Results posted
- A Study of IMC-1121B (Ramucirumab) in Colorectal CancerCompletedNCT00862784Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung CancerCompletedNCT00735696Phase 2Results posted
- Study of Ramucirumab in Ovarian CancerCompletedNCT00721162Phase 2Results posted
- Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast CancerCompletedNCT00703326Phase 3Results posted
- A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate CancerCompletedNCT00683475Phase 2Results posted
- Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With ChemotherapyCompletedNCT00627042Phase 2Results posted
- A Study of Ramucirumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT00515697Phase 2Results posted
- Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyActive, not recruitingNCT06680622Phase 2
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedNCT06542731Phase 1
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingNCT06251973Phase 2
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerActive, not recruitingNCT06007937Phase 1/2
- Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT05980000Phase 2
- Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male VolunteersCompletedNCT05800418Phase 1
- Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3
- Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCWithdrawnNCT05007769Phase 2
- Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)Status unknownNCT04888663Phase 1/2
- A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)TerminatedNCT04675983Phase 3
- Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal JunctionCompletedNCT04517747Not applicable
- Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeActive, not recruitingNCT04340882Phase 2
- Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint InhibitorWithdrawnNCT04179110Phase 2
- Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal AdenocarcinomaStatus unknownNCT03966118Phase 2
- Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)Active, not recruitingNCT03921671Phase 2